Skip to main content
Top
Published in: Infection 1/2011

01-02-2011 | Brief Report

Is procalcitonin a marker of invasive bacterial infection in acute sickle-cell vaso-occlusive crisis?

Authors: K. Stankovic Stojanovic, O. Steichen, F. Lionnet, C. Bachmeyer, I. Lecomte, V. Avellino, G. Grateau, R. Girot, G. Lefevre

Published in: Infection | Issue 1/2011

Login to get access

Abstract

Fever is often present during painful vaso-occlusive crisis (VOC) in sickle-cell disease (SCD), but does not always indicate infection. The aim of our study was to test procalcitonin as a marker of invasive bacterial infection in VOC. Consecutive SCD adults hospitalized for VOC were included. Data were collected at admission and within 24 h after the onset of fever. We distinguished patients with clinically defined and microbiologically documented invasive bacterial infection from patients with no evidence of invasive bacterial infection and who fared well without antibiotics. One hundred and twelve patients were enrolled (61% females, median age 23 years, 88% homozygous SCD). All patients with procalcitonin (PCT) level ≥1 μg/L had an invasive bacterial infection, but two patients (33%) with an invasive bacterial infection had a PCT level <1 μg/L. High levels of PCT indicate invasive bacterial infection. However, a single low PCT level without follow-up measurement cannot rule out an invasive bacterial infection and should not withhold the prescription of antibiotics.
Literature
1.
go back to reference Tang H, Huang T, Jing J, Shen H, Cui W. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection. 2009;37:497–507.PubMedCrossRef Tang H, Huang T, Jing J, Shen H, Cui W. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection. 2009;37:497–507.PubMedCrossRef
2.
go back to reference Monneret G, Laroche B, Bienvenu J. Procalcitonin is not produced by circulating blood cells. Infection. 1999;27:34–5.PubMedCrossRef Monneret G, Laroche B, Bienvenu J. Procalcitonin is not produced by circulating blood cells. Infection. 1999;27:34–5.PubMedCrossRef
3.
go back to reference Brunkhorst FM, Eberhard OK, Brunkhorst R. Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by procalcitonin. Crit Care Med. 1999;27:2172–6.PubMedCrossRef Brunkhorst FM, Eberhard OK, Brunkhorst R. Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by procalcitonin. Crit Care Med. 1999;27:2172–6.PubMedCrossRef
4.
go back to reference Viallon A, Zeni F, Lambert C, Pozzetto B, Tardy B, Venet C, Bertrand JC. High sensitivity and specificity of serum procalcitonin levels in adults with bacterial meningitis. Clin Infect Dis. 1999;28:1313–6.PubMedCrossRef Viallon A, Zeni F, Lambert C, Pozzetto B, Tardy B, Venet C, Bertrand JC. High sensitivity and specificity of serum procalcitonin levels in adults with bacterial meningitis. Clin Infect Dis. 1999;28:1313–6.PubMedCrossRef
5.
go back to reference Rau B, Steinbach G, Gansauge F, Mayer JM, Grünert A, Beger HG. The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis. Gut. 1997;41:832–40.PubMedCrossRef Rau B, Steinbach G, Gansauge F, Mayer JM, Grünert A, Beger HG. The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis. Gut. 1997;41:832–40.PubMedCrossRef
6.
go back to reference Kuse ER, Langefeld I, Jaeger K, Külpmann WR. Procalcitonin in fever of unknown origin after liver transplantation: a variable to differentiate acute rejection from infection. Crit Care Med. 2000;28:555–9.PubMedCrossRef Kuse ER, Langefeld I, Jaeger K, Külpmann WR. Procalcitonin in fever of unknown origin after liver transplantation: a variable to differentiate acute rejection from infection. Crit Care Med. 2000;28:555–9.PubMedCrossRef
8.
go back to reference Hausfater P, Garric S, Ayed SB, Rosenheim M, Bernard M, Riou B. Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study. Clin Infect Dis. 2002;34:895–901.PubMedCrossRef Hausfater P, Garric S, Ayed SB, Rosenheim M, Bernard M, Riou B. Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study. Clin Infect Dis. 2002;34:895–901.PubMedCrossRef
9.
go back to reference Guyatt GH, Tugwell PX, Feeny DH, Haynes RB, Drummond M. A framework for clinical evaluation of diagnostic technologies. CMAJ. 1986;134:587–94.PubMed Guyatt GH, Tugwell PX, Feeny DH, Haynes RB, Drummond M. A framework for clinical evaluation of diagnostic technologies. CMAJ. 1986;134:587–94.PubMed
10.
11.
go back to reference Scott LK, Grier LR, Arnold TC, Conrad SA. Serum procalcitonin concentration as a negative predictor of serious bacterial infection in acute sickle cell pain crisis. Med Sci Monit. 2003;9:CR426–31.PubMed Scott LK, Grier LR, Arnold TC, Conrad SA. Serum procalcitonin concentration as a negative predictor of serious bacterial infection in acute sickle cell pain crisis. Med Sci Monit. 2003;9:CR426–31.PubMed
Metadata
Title
Is procalcitonin a marker of invasive bacterial infection in acute sickle-cell vaso-occlusive crisis?
Authors
K. Stankovic Stojanovic
O. Steichen
F. Lionnet
C. Bachmeyer
I. Lecomte
V. Avellino
G. Grateau
R. Girot
G. Lefevre
Publication date
01-02-2011
Publisher
Springer-Verlag
Published in
Infection / Issue 1/2011
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-010-0072-6

Other articles of this Issue 1/2011

Infection 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine